PASCHA CHAFIN: Open Payments
NPI 1457604993 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$648 in 25 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $611 · 2025 $648
Food & beverage: $598Education: $50
| Company | Payments | Amount |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 4 | $118 |
| Merck Sharp & Dohme LLC | 4 | $94 |
| Novartis Pharmaceuticals Corporation | 3 | $78 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $72 |
| W. L. Gore & Associates, Inc. | 1 | $50 |
| Boston Scientific Corporation | 1 | $39 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $33 |
| Edwards Lifesciences Corporation | 1 | $29 |
| Esperion Therapeutics, Inc. | 1 | $28 |
| Novo Nordisk Inc | 1 | $24 |
Products named: AMVUTTRA, VERQUVO, LEQVIO, JARDIANCE, GORE-TEX Vascular Graft, Varithena Administration Pack, Kerendia, SAPIEN 3 Ultra RESILIA.
Industry payments across GA — which companies pay providers there.
